Anti-tumor Effect of Ixabepilone in Metastatic Breast Cancer (mBC) Selected by the Ixabepilone DRP.
Allarity Therapeutics
Allarity Therapeutics
Takeda
Fusion Pharmaceuticals Inc.
Novartis
Sanofi
Bolt Biotherapeutics, Inc.
Pfizer
Taiho Oncology, Inc.
Tempus AI
Incyte Corporation
Actym Therapeutics, Inc.
Taiho Oncology, Inc.
Novartis
Zenith Epigenetics
Palleos Healthcare GmbH
Sanofi
Sanofi
Bolt Biotherapeutics, Inc.
Sanofi
Sanofi
SBI ALApharma Canada, Inc.
Alaunos Therapeutics
Alaunos Therapeutics
Eli Lilly and Company
Hoffmann-La Roche
Eli Lilly and Company
Sanofi
Lyell Immunopharma, Inc.
Lyell Immunopharma, Inc.
Daiichi Sankyo
Biogen
Context Therapeutics Inc.
AstraZeneca
Pfizer
NextCure, Inc.
Elevation Oncology
Valerio Therapeutics
Turnstone Biologics, Corp.
Tvardi Therapeutics, Incorporated
Eurofarma Laboratorios S.A.
Accutar Biotechnology Inc
Lumicell, Inc.
NantBioScience, Inc.
Deciphera Pharmaceuticals, LLC
Aminex Therapeutics, Inc.
Five Prime Therapeutics, Inc.
Astellas Pharma Inc
Hoffmann-La Roche
AstraZeneca
Novartis